Arcturus Therapeutics says cash runway now extends to 2026

In its Q4 results last night, Arcturus Therapeutics stated: "The Company’s cash balance totaled $391.9 million at December 31, 2022, compared to a cash balance of $370.5 million at December 31, 2021. In March 2023, the Company repaid Singapore $17.1 million which triggered the elimination of $33.3 million in non-recourse debt pertaining to the ARCT-021 program." Andrew Sassine, CFO of Arcturus Therapeutics, also noted: "Within the first four months of our CSL collaboration, we successfully achieved multiple program objectives, triggering $90 million in milestone payments. Additionally, with the elimination of $33.3 million of non-recourse debt to Singapore, our cash runway now extends into the beginning of 2026."